by Drs. Pan, Doctor & Spinella
at Washington University in St. Louis (WUSTL)

  • Bench Pilot Work
    Formulation demonstrates key requirements
    Novel transfusion models
  • First in vivo POC
    Efficacy for hemorrhagic shock and 70% blood exchange
    Formulation ErythroMer (EM) V1
  • First Funding & Support
    Children’s Discovery Institute OAIF Grant ($1M)
    Invention Disclosure (WUSTL)
    Bear Cub award ($75K)
  • Incubator Program: BioGenerator Fundamentals